-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Barinthus Biotherapeutics, Maintains $5 Price Target

Benzinga·11/19/2024 09:30:12
Listen to the news
HC Wainwright & Co. analyst Yi Chen reiterates Barinthus Biotherapeutics (NASDAQ:BRNS) with a Buy and maintains $5 price target.